{
    "hands_on_practices": [
        {
            "introduction": "A fundamental first step in deciphering the function of a newly discovered lncRNA is to determine its subcellular location. This practice introduces a core bioinformatic skill: calculating a localization enrichment score from RNA-sequencing data obtained from separated nuclear and cytoplasmic fractions . By quantifying the distribution of the lncRNA, you can form a strong, evidence-based hypothesis about whether its primary role lies in nuclear processes like transcription or cytoplasmic processes like regulating messenger RNA stability.",
            "id": "5024931",
            "problem": "In medical genetics, the Central Dogma of Molecular Biology states that deoxyribonucleic acid (DNA) is transcribed into ribonucleic acid (RNA), which is translated into protein, and long non-coding RNA (lncRNA) is a class of RNA that does not encode protein but can regulate gene expression through diverse mechanisms. A well-tested observation is that the subcellular localization of an lncRNA often constrains its predominant mechanism of action: nuclear-enriched lncRNAs frequently modulate chromatin architecture or transcription, whereas cytoplasmic-enriched lncRNAs often influence messenger RNA (mRNA) stability, translation, or act as competing endogenous RNAs. Cellular fractionation followed by RNA sequencing (RNA-seq) quantifies transcript abundance in compartments, commonly reported as transcripts per million (TPM). A widely used quantitative summary of localization is the enrichment score defined as the base-2 logarithm of the nuclear-to-cytoplasmic abundance ratio.\n\nYou are given RNA-seq TPM values for a single lncRNA measured in two fractions: nucleus with $TPM_{\\text{nucleus}} = 5$ and cytoplasm with $TPM_{\\text{cytoplasm}} = 0.5$. Using the standard enrichment score $S$ defined by\n$$\nS = \\log_{2}\\!\\left(\\frac{TPM_{\\text{nucleus}}}{TPM_{\\text{cytoplasm}}}\\right),\n$$\ncompute $S$ and round your result to four significant figures. Report $S$ as a dimensionless decimal number. Then, based on the sign and magnitude of $S$, state how this quantitative result informs a mechanistic hypothesis about whether the lncRNA is more likely to act through nuclear processes (for example, transcriptional or chromatin regulation) or through cytoplasmic processes (for example, post-transcriptional regulation). The final numerical answer must be the calculated value of $S$ only; the qualitative interpretation should be provided in your reasoning.",
            "solution": "The problem is deemed valid as it is scientifically grounded in molecular biology and bioinformatics, well-posed with a clear formula and data, and objective in its language. It is self-contained and free of contradictions.\n\nThe problem asks for the computation and interpretation of a subcellular enrichment score, $S$, for a long non-coding RNA (lncRNA). The score is defined by the formula:\n$$\nS = \\log_{2}\\!\\left(\\frac{TPM_{\\text{nucleus}}}{TPM_{\\text{cytoplasm}}}\\right)\n$$\nwhere $TPM_{\\text{nucleus}}$ and $TPM_{\\text{cytoplasm}}$ are the abundance measurements in the nucleus and cytoplasm, respectively, reported in units of transcripts per million ($TPM$).\n\nThe given values from the RNA sequencing experiment are:\n$$\nTPM_{\\text{nucleus}} = 5\n$$\n$$\nTPM_{\\text{cytoplasm}} = 0.5\n$$\nSubstituting these values into the definition of $S$:\n$$\nS = \\log_{2}\\!\\left(\\frac{5}{0.5}\\right)\n$$\nFirst, we evaluate the ratio inside the logarithm:\n$$\n\\frac{5}{0.5} = 10\n$$\nThis simplifies the expression for $S$ to:\n$$\nS = \\log_{2}(10)\n$$\nTo obtain a numerical value, we can use the change of base formula for logarithms, which states that $\\log_{b}(a) = \\frac{\\ln(a)}{\\ln(b)}$. Using the natural logarithm ($\\ln$):\n$$\nS = \\frac{\\ln(10)}{\\ln(2)}\n$$\nUsing the standard numerical values for these logarithms:\n$$\nS \\approx \\frac{2.30258509...}{0.69314718...} \\approx 3.32192809...\n$$\nThe problem requires the result to be rounded to four significant figures. The calculated value is $3.32192809...$. The first four significant figures are $3$, $3$, $2$, and $1$. The fifth significant figure is $9$, which is $\\ge 5$, so we must round up the fourth significant figure.\n$$\nS \\approx 3.322\n$$\nThis is the dimensionless decimal value for the enrichment score.\n\nFor the second part of the task, we must state how this quantitative result informs a mechanistic hypothesis. The sign of the enrichment score $S$ indicates the compartment of enrichment.\n- If $S > 0$, then $\\log_{2}(\\frac{TPM_{\\text{nucleus}}}{TPM_{\\text{cytoplasm}}}) > 0$, which implies $\\frac{TPM_{\\text{nucleus}}}{TPM_{\\text{cytoplasm}}} > 2^0 = 1$. This indicates nuclear enrichment.\n- If $S < 0$, this would imply cytoplasmic enrichment.\n- If $S = 0$, this would imply equal distribution between the two compartments.\n\nIn this case, $S \\approx 3.322$, which is a positive value. This signifies that the lncRNA is enriched in the nucleus. The magnitude of the score indicates the degree of enrichment; the ratio of nuclear to cytoplasmic abundance is $2^S = 2^{\\log_2(10)} = 10$. This means the lncRNA is $10$ times more abundant in the nucleus than in the cytoplasm.\n\nBased on the biological premise provided in the problem statement—\"nuclear-enriched lncRNAs frequently modulate chromatin architecture or transcription\"—the strong nuclear enrichment ($S \\approx 3.322$) supports the hypothesis that this lncRNA is most likely to function within the nucleus. Its primary mechanism of action would be predicted to involve nuclear processes, such as transcriptional regulation (e.g., acting as a scaffold for transcription factors) or modulation of chromatin structure (e.g., interacting with chromatin-modifying enzymes), rather than cytoplasmic processes like interfering with mRNA translation or stability.",
            "answer": "$$\\boxed{3.322}$$"
        },
        {
            "introduction": "Once a lncRNA is found to be enriched in the nucleus, a common hypothesis is that it functions by regulating the local chromatin environment. This exercise simulates the analysis of a Chromatin Immunoprecipitation sequencing (ChIP-seq) experiment, a powerful technique to map protein-DNA interactions and histone modifications across the genome . You will calculate the change in a repressive histone mark after depleting a lncRNA, allowing you to directly test its proposed role in epigenetic silencing.",
            "id": "5024955",
            "problem": "A long non-coding RNA (lncRNA) is hypothesized to recruit Polycomb Repressive Complex 2 (PRC2) to a specific locus, thereby increasing trimethylation of lysine 27 on histone H3 (H3K27me3), a chromatin mark widely associated with transcriptional repression. You perform Chromatin Immunoprecipitation followed by sequencing (ChIP-seq) for H3K27me3 in control cells and after lncRNA knockdown, using standard normalization to correct for library size and mapping biases. Assume normalized ChIP-seq read density is proportional to mark occupancy at the locus, and that decreased H3K27me3 occupancy is evidence against ongoing repression at that locus. At the locus of interest, the normalized read counts are $120$ in control and $60$ after lncRNA knockdown.\n\nUsing only the above foundational facts and the definition that fold change is the ratio of the post-perturbation signal to the pre-perturbation signal, compute the base-$2$ logarithm of the fold change in H3K27me3 at this locus (after knockdown relative to control). Use the sign of this value to reason whether the lncRNA likely promotes repression at this locus, but report only the base-$2$ logarithmic fold change as your final numerical answer. Provide the exact value as a pure number with no units.",
            "solution": "The problem is validated as scientifically grounded, well-posed, objective, and self-contained. All necessary data, definitions, and assumptions are provided to reach a unique and meaningful solution.\n\nThe task is to compute the base-$2$ logarithm of the fold change in the normalized read counts for the H3K27me3 histone mark, following the knockdown of a long non-coding RNA (lncRNA).\n\nLet $S_{control}$ be the normalized read count in the control condition (pre-perturbation) and $S_{knockdown}$ be the normalized read count in the lncRNA knockdown condition (post-perturbation).\n\nFrom the problem statement, the given values are:\n$$S_{control} = 120$$\n$$S_{knockdown} = 60$$\n\nThe problem defines fold change, which we will denote as $FC$, as the ratio of the post-perturbation signal to the pre-perturbation signal. In this context:\n$$FC = \\frac{S_{post-perturbation}}{S_{pre-perturbation}} = \\frac{S_{knockdown}}{S_{control}}$$\n\nSubstituting the given numerical values into the expression for fold change:\n$$FC = \\frac{60}{120} = \\frac{1}{2}$$\n\nThe problem requires the calculation of the base-$2$ logarithm of this fold change, denoted as $\\log_{2}(FC)$.\n$$\\log_{2}(FC) = \\log_{2}\\left(\\frac{1}{2}\\right)$$\n\nUsing the properties of logarithms, specifically that $\\log_{b}(x^y) = y \\log_{b}(x)$ and $\\frac{1}{2} = 2^{-1}$:\n$$\\log_{2}\\left(\\frac{1}{2}\\right) = \\log_{2}(2^{-1})$$\n$$= -1 \\cdot \\log_{2}(2)$$\n\nSince $\\log_{b}(b) = 1$, it follows that $\\log_{2}(2) = 1$.\nTherefore:\n$$\\log_{2}(FC) = -1 \\cdot 1 = -1$$\n\nThe base-$2$ logarithm of the fold change is $-1$.\n\nFor completeness, we can use the sign of this value to reason about the biological hypothesis. The hypothesis is that the lncRNA promotes repression by recruiting PRC2, which deposits the repressive H3K27me3 mark. A negative $\\log_2(FC)$ value, such as $-1$, indicates that the fold change is less than $1$, meaning the signal has decreased after the perturbation. Here, the perturbation is the knockdown of the lncRNA, and the signal is the abundance of the H3K27me3 mark. The observed decrease in H3K27me3 upon lncRNA knockdown is consistent with the hypothesis that the lncRNA is required for the deposition or maintenance of this repressive mark at the locus.\n\nHowever, the problem explicitly requests only the numerical value of the base-$2$ logarithmic fold change as the final answer.",
            "answer": "$$\\boxed{-1}$$"
        },
        {
            "introduction": "The ultimate proof of a lncRNA's function often requires a meticulously designed experiment that can distinguish between local (*cis*) and diffusible (*trans*) modes of action. This problem challenges you to step into the role of an experimental biologist and evaluate proposed strategies for a 'rescue' experiment . Your task is to identify the most rigorous design that can definitively prove a lncRNA acts in *trans* by re-introducing it at a distant genomic location and assessing its ability to restore gene expression, complete with the necessary controls to ensure the conclusion is sound.",
            "id": "5024959",
            "problem": "A biomedical research team studies a novel long non-coding RNA (lncRNA), provisionally named Glioma-Regulatory Antisense 1 (GLIO-AS1), which is dysregulated in glioblastoma and associated with reduced expression of Phosphatase and Tensin Homolog (PTEN). They hypothesize that GLIO-AS1 positively regulates PTEN in trans. Using well-tested biological principles, including the Central Dogma of Molecular Biology (DNA $\\to$ RNA $\\to$ protein), the definition that a cis-acting lncRNA acts locally on nearby loci while a trans-acting lncRNA acts on distant loci or chromosomes, and the concept of a genomic safe harbor locus (for example, Adeno-Associated Virus Integration Site 1 (AAVS1)) that permits stable, position-independent expression, design a rescue experiment to test the trans hypothesis and define quantitative criteria for declaring a bona fide trans effect.\n\nExperimental context: The team has generated GLIO-AS1 knockout glioblastoma cell lines by deleting its promoter and first exon using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated protein 9 (CRISPR-Cas9). In the knockout, PTEN messenger RNA (mRNA) and protein are reduced relative to wild-type. They can integrate complementary DNA (cDNA) constructs into AAVS1 and quantify mRNA by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and protein by immunoblotting. They can titrate GLIO-AS1 expression using a doxycycline-inducible promoter to approximate wild-type levels.\n\nWhich option most appropriately proposes a rescue experiment using ectopic expression from a safe harbor locus and specifies quantitative criteria that are sufficient to declare a trans effect, ruling out cis or position effects?\n\nA. Integrate a GLIO-AS1 cDNA into AAVS1 under a doxycycline-inducible promoter in GLIO-AS1 knockout cells; include controls of empty vector at AAVS1 and a scrambled-sequence RNA of matched length at AAVS1. Titrate induction so GLIO-AS1 steady-state RNA level matches wild-type within $0.8$–$1.2\\times$ (as measured by RT-qPCR). Define rescue if, upon induction, PTEN mRNA and protein in knockout cells return to within $0.8$–$1.2\\times$ of the wild-type mean and differ significantly from knockout plus empty vector controls by a two-sided $t$-test with $p<0.05$ and a false discovery rate $q<0.10$ (Benjamini–Hochberg). Demonstrate a dose-response with GLIO-AS1 level and PTEN level across at least $3$ induction points with Pearson correlation $r\\ge 0.7$ and slope $>0$. Confirm that reintroduction of the GLIO-AS1 promoter without producing RNA does not rescue, and that genes flanking AAVS1 do not change by more than $1.2\\times$, ruling out position effects.\n\nB. Reinsert the GLIO-AS1 promoter at its endogenous locus without expressing RNA and measure nearby gene expression. Declare a trans effect if any neighbor returns to within $0.8$–$1.2\\times$ of wild-type with $p<0.05$.\n\nC. Overexpress GLIO-AS1 from random lentiviral insertions at $\\ge 5\\times$ wild-type level in knockout cells and declare a trans effect if PTEN mRNA increases above knockout baseline with $p<0.20$; no empty vector or scrambled controls are needed if the effect size exceeds $1.5\\times$.\n\nD. Integrate GLIO-AS1 cDNA into AAVS1 in knockout cells without matching expression to wild-type and define rescue as any significant increase in PTEN protein ($p<0.05$). Rule out cis effects by showing that a minimal promoter alone at AAVS1 fails to change PTEN, without testing for dose-response or monitoring AAVS1-flanking genes.\n\nE. Express an unrelated protein-coding gene from AAVS1 to control for integration and declare a trans effect if glioblastoma cell proliferation is reduced by $\\ge 20\\%$ compared to knockout baseline, regardless of PTEN changes.\n\nSelect the single best option.",
            "solution": "The user has requested a meticulous validation of the problem statement, followed by a derivation of the correct answer and a critical evaluation of all provided options.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **LncRNA of interest:** `GLIO-AS1` (Glioma-Regulatory Antisense 1), a novel long non-coding RNA.\n*   **Disease context:** Dysregulated in glioblastoma.\n*   **Initial Observation:** `GLIO-AS1` dysregulation is associated with reduced expression of `PTEN` (Phosphatase and Tensin Homolog).\n*   **Hypothesis:** `GLIO-AS1` positively regulates `PTEN` in *trans*.\n*   **Provided Definitions:**\n    *   Central Dogma of Molecular Biology: DNA $\\to$ RNA $\\to$ protein.\n    *   *cis*-acting lncRNA: Acts on nearby loci.\n    *   *trans*-acting lncRNA: Acts on distant loci or different chromosomes.\n    *   Genomic safe harbor locus (e.g., `AAVS1`): Allows for stable, position-independent gene expression upon integration.\n*   **Task:** Design a rescue experiment to test the *trans* hypothesis and define quantitative criteria for a bona fide *trans* effect.\n*   **Available Experimental System:**\n    *   `GLIO-AS1` knockout (KO) glioblastoma cells, created by deleting its promoter and first exon via CRISPR-Cas9.\n    *   In KO cells, `PTEN` messenger RNA (mRNA) and protein levels are reduced compared to wild-type (WT) cells.\n    *   Researchers can integrate complementary DNA (cDNA) constructs into the `AAVS1` safe harbor locus.\n    *   Expression can be controlled using a doxycycline-inducible promoter to titrate RNA levels.\n    *   mRNA can be quantified by RT-qPCR; protein can be quantified by immunoblotting.\n*   **Question:** Identify the option that best proposes a rescue experiment using ectopic expression from a safe harbor locus and specifies sufficient quantitative criteria to declare a *trans* effect while ruling out *cis* or position effects.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded:** The problem is firmly grounded in established principles of molecular genetics and cancer biology. The concepts of lncRNA function, *cis*/*trans* regulation, gene knockout, rescue experiments, safe harbor loci (`AAVS1`), inducible expression systems, and standard molecular quantification techniques (RT-qPCR, immunoblotting) are all fundamental to the field.\n2.  **Well-Posed:** The problem is well-posed. It presents a clear, testable scientific hypothesis and provides a defined set of experimental tools and a cellular context. The task is to evaluate proposed experimental designs, for which a single best answer can be determined based on established standards of scientific rigor.\n3.  **Objective:** The problem statement is objective, using precise, unbiased technical language. It is free of subjective claims.\n4.  **Scientific or Factual Unsoundness:** There are no scientific or factual errors. The premise that a lncRNA can regulate a tumor suppressor gene like `PTEN` in *trans* is a known and actively researched mechanism in cancer. All described techniques are standard and plausible.\n5.  **Incomplete or Contradictory Setup:** The setup is self-contained and complete. It provides all the necessary background (observation, hypothesis, available tools) to design and evaluate the proposed rescue experiment. There are no internal contradictions.\n6.  **Unrealistic or Infeasible:** The described experimental plan is fully realistic and feasible in a moderately equipped molecular biology laboratory.\n7.  **Ill-Posed or Poorly Structured:** The problem is clearly structured and asks a specific question about experimental design.\n8.  **Other Flaws:** The problem is not trivial, pseudo-profound, or tautological. It addresses a genuine challenge in establishing a causal, mechanistic link between a non-coding RNA and its target gene.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. It is a well-formulated question in experimental design within the field of medical genetics. The solution process may proceed.\n\n### Derivation of the Correct Solution\n\nThe central goal is to design a \"rescue\" experiment that rigorously tests the hypothesis that the `GLIO-AS1` RNA molecule acts in *trans* to positively regulate `PTEN` expression. A gold-standard experimental design must accomplish three things:\n1.  Demonstrate that re-introducing `GLIO-AS1` RNA in a cell lacking it (`GLIO-AS1` KO) restores `PTEN` expression.\n2.  Prove that this effect is due to the `GLIO-AS1` RNA acting in *trans* (i.e., as a diffusible molecule) and not due to an artifact of the experimental manipulation.\n3.  Provide stringent quantitative benchmarks for what constitutes a successful rescue.\n\nTo test for a *trans* effect, the `GLIO-AS1` gene must be expressed from a genomic location different from its native locus. The use of a \"safe harbor\" locus like `AAVS1` is ideal because it is a well-characterized genomic site where transgenes can be expressed without disrupting local gene function or being silenced, thereby minimizing \"position effects.\"\n\nA rigorous experiment would proceed as follows:\n1.  **System:** Use the `GLIO-AS1` KO glioblastoma cells, where the baseline `PTEN` level is low.\n2.  **Rescue Construct:** Integrate a cDNA construct for `GLIO-AS1` into the `AAVS1` locus. To avoid artifacts from massive overexpression, the expression should be controlled, ideally with an inducible promoter (like a doxycycline-inducible system), to approximate endogenous, wild-type expression levels.\n3.  **Negative Controls:** Several controls are essential:\n    *   **Empty Vector Control:** Integrate the same vector but without the `GLIO-AS1` cDNA into `AAVS1`. This controls for any effects of the integration event, the vector itself, or the induction process (e.g., doxycycline treatment). This is the primary baseline for comparison.\n    *   **Sequence-Nonspecific Control:** Express an RNA of similar length and composition but with a scrambled, non-functional sequence. This ensures the observed effect is specific to the `GLIO-AS1` sequence/structure, not a generic effect of transcribing any long RNA.\n4.  **Confounder Controls:**\n    *   **Position Effect Control:** Measure the expression of genes immediately flanking the `AAVS1` integration site. If their expression is unchanged, it confirms the \"safe harbor\" is behaving as expected and the observed effect on `PTEN` is not an artifact of disrupting the `AAVS1` locus.\n5.  **Quantitative Criteria:**\n    *   The `GLIO-AS1` RNA level upon induction should be returned to a physiological range, e.g., within $0.8$ to $1.2$ times the wild-type level.\n    *   \"Rescue\" of `PTEN` should be defined as its mRNA and protein levels returning to a similar near-wild-type range.\n    *   The change in `PTEN` in the rescued cells must be statistically significant compared to the empty vector control, using appropriate statistical tests (e.g., a $t$-test with $p < 0.05$). To account for multiple comparisons, correcting for the false discovery rate ($q < 0.10$) is a sign of high rigor.\n    *   A dose-response relationship, where titrating `GLIO-AS1` levels with varying doxycycline concentrations leads to a corresponding, correlated change in `PTEN` levels, provides powerful evidence for a causal link. This can be quantified with a Pearson correlation coefficient ($r$) and a positive slope.\n\nWith these principles established, each option can be critically evaluated.\n\n### Option-by-Option Analysis\n\n**A. Integrate a GLIO-AS1 cDNA into AAVS1 under a doxycycline-inducible promoter in GLIO-AS1 knockout cells; include controls of empty vector at AAVS1 and a scrambled-sequence RNA of matched length at AAVS1. Titrate induction so GLIO-AS1 steady-state RNA level matches wild-type within $0.8$–$1.2\\times$ (as measured by RT-qPCR). Define rescue if, upon induction, PTEN mRNA and protein in knockout cells return to within $0.8$–$1.2\\times$ of the wild-type mean and differ significantly from knockout plus empty vector controls by a two-sided $t$-test with $p<0.05$ and a false discovery rate $q<0.10$ (Benjamini–Hochberg). Demonstrate a dose-response with GLIO-AS1 level and PTEN level across at least $3$ induction points with Pearson correlation $r\\ge 0.7$ and slope $>0$. Confirm that reintroduction of the GLIO-AS1 promoter without producing RNA does not rescue, and that genes flanking AAVS1 do not change by more than $1.2\\times$, ruling out position effects.**\n\nThis option describes a state-of-the-art, rigorous experiment. It correctly uses a safe harbor locus (`AAVS1`) to test for a *trans* effect. It employs an inducible promoter to achieve physiological expression levels, avoiding overexpression artifacts. It includes the two most critical negative controls: an empty vector and a scrambled sequence RNA. The quantitative criteria are stringent and appropriate, including a return to near-WT levels, robust statistical tests with FDR correction, and a requirement for a dose-response relationship. Finally, it explicitly proposes to check for position effects by monitoring flanking genes and includes an additional control to rule out function of the promoter DNA itself. This design is comprehensive and directly addresses the hypothesis while controlling for all major confounders.\n\nVerdict: **Correct**\n\n**B. Reinsert the GLIO-AS1 promoter at its endogenous locus without expressing RNA and measure nearby gene expression. Declare a trans effect if any neighbor returns to within $0.8$–$1.2\\times$ of wild-type with $p<0.05$.**\n\nThis experiment is fundamentally flawed. It is designed to test for a *cis*-regulatory function of the promoter DNA element on neighboring genes. It does not re-express the `GLIO-AS1` RNA, and therefore cannot test the hypothesis about the RNA's function. Furthermore, it measures the wrong genes (neighbors, not the distant `PTEN`) and draws an illogical conclusion, declaring a *trans* effect from a *cis* experiment.\n\nVerdict: **Incorrect**\n\n**C. Overexpress GLIO-AS1 from random lentiviral insertions at $\\ge 5\\times$ wild-type level in knockout cells and declare a trans effect if PTEN mRNA increases above knockout baseline with $p<0.20$; no empty vector or scrambled controls are needed if the effect size exceeds $1.5\\times$.**\n\nThis design has multiple severe flaws. First, overexpression ($\\ge 5\\times$ WT) is prone to producing non-physiological, artifactual results. Second, random lentiviral integration introduces uncontrolled position effects and insertional mutagenesis, a major confounder that the use of a safe harbor locus is designed to avoid. Third, the proposal that essential controls (empty vector) are unnecessary is a gross violation of scientific principles. Fourth, the statistical threshold of $p<0.20$ is unacceptably lenient and would result in a very high false-positive rate.\n\nVerdict: **Incorrect**\n\n**D. Integrate GLIO-AS1 cDNA into AAVS1 in knockout cells without matching expression to wild-type and define rescue as any significant increase in PTEN protein ($p<0.05$). Rule out cis effects by showing that a minimal promoter alone at AAVS1 fails to change PTEN, without testing for dose-response or monitoring AAVS1-flanking genes.**\n\nThis is a much weaker version of option A. While it correctly uses the `AAVS1` locus, it fails on several points of rigor. By not matching expression to WT levels, it is open to overexpression artifacts. Defining rescue as *any* significant increase is a weak criterion; a biologically meaningful rescue should restore levels to near-normal. The omission of a dose-response test weakens the evidence for causality. Most importantly, failing to monitor genes flanking `AAVS1` means it does not properly control for position effects.\n\nVerdict: **Incorrect**\n\n**E. Express an unrelated protein-coding gene from AAVS1 to control for integration and declare a trans effect if glioblastoma cell proliferation is reduced by $\\ge 20\\%$ compared to knockout baseline, regardless of PTEN changes.**\n\nThis experiment is irrelevant to the hypothesis. It does not involve re-expressing `GLIO-AS1`, so it is not a rescue experiment. It measures a downstream cellular phenotype (proliferation) instead of the direct molecular target (`PTEN` expression) that formed the basis of the hypothesis. Declaring an effect \"regardless of PTEN changes\" divorces the conclusion from the mechanism being investigated.\n\nVerdict: **Incorrect**\n\nBased on the analysis, option A is the only one that proposes a scientifically rigorous, well-controlled, and appropriately quantified experiment to test the given hypothesis.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}